
- /
- Supported exchanges
- / KQ
- / 199800.KQ
ToolGen Inc. (199800 KQ) stock market data APIs
ToolGen Inc. Financial Data Overview
ToolGen Incorporated, a biotechnology company, focuses on the development of genome editing technology in South Korea. The company develops clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene scissors for gene editing in eukaryotic cells. It is involved in patent monetization, treatment, and seed businesses. ToolGen Incorporated was founded in 1999 and is based in Seoul, South Korea.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get ToolGen Inc. data using free add-ons & libraries
Get ToolGen Inc. Fundamental Data
ToolGen Inc. Fundamental data includes:
- Net Revenue: 882 M
- EBITDA: -19 724 804 096
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ToolGen Inc. News
![[Latest] Global CRISPR Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)](/build/assets/fallback3-CioIYWIa.jpg)
[Latest] Global CRISPR Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global CRISPR Gene Editing Market size & share reven...


OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease
SUWON, South Korea, June 15, 2022—(BUSINESS WIRE)—OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, today announced that the Company’s subsidiary mCureX Therapeutics, Inc. ha...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.